Immune Checkpoint Inhibitors Market, by Inhibitor Type (CTLA-4 Inhibitors, PD-1 Inhibitors, Others), Application (Hodgkin Lymphoma, Kidney Cancers, Melanoma, Non-small Cell Lung Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region (North America, Europe, Asia-Pacific, and the Rest of the World).
Immune Checkpoint Inhibitors Market, by Inhibitor Type (CTLA-4 Inhibitors, PD-1 Inhibitors, Others), Application (Hodgkin Lymphoma, Kidney Cancers, Melanoma, Non-small Cell Lung Cancer, Others), Distribution Channel ...
"The global immune checkpoint inhibitors market is likely to rebound at a significant CAGR of 18.2%."
The global market for immune checkpoint inhibitors (ICIs) was growing at a rapid pace and was expected to continue its upward trajectory in the coming years. ICIs are a type of cancer immunotherapy that works by blocking the signals that cancer cells use to evade the immune system.
Some of the key market highlights of the ICI market include:
Increasing prevalence of cancer: The incidence of cancer is increasing globally, which is driving the demand for more effective cancer treatments like ICIs.
FDA approvals: The FDA has approved several ICIs for the treatment of various cancers, including melanoma, lung cancer, and bladder cancer. This has increased the adoption of ICIs among healthcare providers and patients.
Growing pipeline of ICIs: There are several ICIs in the pipeline that are expected to be approved in the coming years, which will further drive market growth.
Strategic collaborations and partnerships: Many pharmaceutical companies are forming strategic collaborations and partnerships to develop and commercialize ICIs, which is expected to increase the availability of ICIs in the market.
High cost: ICIs are expensive, which can limit their adoption among patients and healthcare providers, particularly in developing countries.
Immune checkpoint inhibitors may be a style of drug utilized in immunotherapy. Although conventional chemotherapeutic drugs remain the first-line option for the treatment of most cancer types, targeted immune therapies are evolving as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the popularity and destruction of cancer cells by the system.
Key Players
Key players operating in the immune checkpoint inhibitors market are:
The Immune Checkpoint Inhibitors (ICI) Market is expected to grow rapidly due to the increasing prevalence of cancer and the rising demand for immunotherapy treatments. Here are some application trends of the ICI Market:
Lung Cancer: Lung cancer is the most prevalent cancer type globally and has been the largest segment in the ICI Market. Immune Checkpoint Inhibitors are increasingly used as a first-line treatment for advanced non-small cell lung cancer.
Melanoma: Melanoma is a type of skin cancer that is known to have a high mutation rate, which makes it an attractive target for immunotherapy. Immune Checkpoint Inhibitors have shown promising results in treating advanced melanoma, and their usage is expected to increase in the future.
Bladder Cancer: Bladder cancer is another segment of the ICI Market that is expected to grow significantly. In recent years, immune checkpoint inhibitors have been approved for the treatment of advanced bladder cancer, and they are being tested in earlier stages of the disease.
Breast Cancer: Although breast cancer has not been a traditional target for immunotherapy, there is a growing interest in using immune checkpoint inhibitors to treat this disease. Researchers are currently testing the effectiveness of these drugs in combination with other treatments.
Colorectal Cancer: Immune checkpoint inhibitors have shown mixed results in treating colorectal cancer. However, researchers are still investigating their potential in combination with other treatments.
COVID-19 Impact
The COVID-19 outbreak moderately affected the growth of the immune checkpoint inhibitors market. Rising cases of coronavirus across the globe put a heavy strain on the healthcare sector. As the medical community is treating the infected patients, the research related to immune checkpoint inhibitors was moderately impacted, thus resulting in fewer visits to clinics.
Segment Analysis
Inhibitor Trends
"The PD-1 inhibitors segment accounted for the largest market share."
The market has been classified into CTLA-4 inhibitors, PD-1 inhibitors, and others. The PD-1 inhibitors segment accounted for a substantial market share in 2020. This is mainly ascribed to the increased volume of research activities, approvals, and surge in prescriptions of these drugs such as nivolumab and pembrolizumab. In addition, the growing adoption of pembrolizumab, the first PD-1 inhibitor since its approval, owing to its proven efficiency to treat multiple FDA-approved indications like melanoma, further boosts segment growth.
Application Trends
"The treatment of canceraccounted for the largest market share."
The market has been classified into Hodgkin lymphoma, kidney cancers, melanoma, non-small cell lung cancer, and others. The dominant application type for immune checkpoint inhibitors (ICIs) is the treatment of cancer. ICIs are a type of immunotherapy that works by targeting proteins in immune cells that regulate immune system activity. By inhibiting these proteins, ICIs can help the immune system recognize and attack cancer cells, leading to improved outcomes for patients with certain types of cancer.
Currently, ICIs are approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, bladder cancer, and Hodgkin's lymphoma, among others. The market for ICIs is expected to continue to grow as new indications are approved and as research uncovers new ways to use these drugs to treat cancer and other diseases.
Regional Insights
"North America accounted for the largest market share."
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the strong presence of well-developed healthcare infrastructure and favorable government initiatives. Moreover, rising innovations in technologically advanced products, immense per capita health expenditures; and the increasing prevalence of various chronic diseases such as skin cancer, diabetes, urothelial carcinomas, and lung cancer further proliferate regional growth.
To know which region offers the best growth opportunities,Register Here
Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market.
What deliverables will you get in this report?
Key questions this report answers
Relevant contents in the report
How big is the sales opportunity?
In-depth analysis of the Immune Checkpoint Inhibitors Market
How lucrative is the future?
Market forecast and trend data and emerging trends
Which regions offer the best sales opportunities?
Global, regional and country level historical data and forecasts
Which are the most attractive market segments?
Market segment analysis and forecast
Which are the top players and their market positioning?
Porter’s five forces analysis, PEST analysis, Life cycle analysis
What are the factors affecting the market?
Drivers & challenges
Will I get the information on my specific requirement?
10% free customization
Research Methodology
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with companies across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.
Customization Options
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Detailed profiling of additional market players (up to three players)
SWOT analysis of key players (up to three players)
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
Immune checkpoint inhibitors may be a style of drug utilized in immunotherapy. Although conventional chemotherapeutic drugs remain the first-line option for the treatment of most cancer types, targeted immune therapies are evolving as standard treatments for advanced-stage cancers. These drugs tar-get cell surface checkpoint proteins to stimulate the popularity and destruction of cancer cells by the system.
Bristol-Myers Squibb Company (US), Merck & Co. (US), F. Hoffmann-La Roche AG (Switzer-land), Regeneron Pharmaceuticals Inc. (US), AstraZeneca PLC (UK), Eli Lilly and Company (AR-MO Biosciences.) (US), Fortress Biotech, Inc. (US), Novartis AG (Switzerland), and Pfizer Inc. (US) are among the key players in the immune checkpoint inhibitors market.
Technological developments in screening procedures for cancer, increase in government initiatives to cure cancer, growing healthcare expenditures, and rise in public awareness are the factors driving the growth of immune checkpoint inhibitors market.
